Actively Recruiting
New Taipei City 888 Digital Medical AI Platform for Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials
Led by New Taipei City Medical Association · Updated on 2026-05-14
4162
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
N
New Taipei City Medical Association
Lead Sponsor
N
National Taiwan University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to evaluate prevention and treatment strategies for chronic conditions known as the "Three Highs"—hypertension, hyperglycemia, and hyperlipidemia—which are major contributors to cardiovascular disease and related complications in Taiwan. The program includes two large-scale cluster-randomized clinical trials within the New Taipei City healthcare network, designed to assess the impact of a mobile digital health platform and the timing of antihypertensive medication on blood pressure control, organ damage, and cardiovascular events. One trial (T-888-DIGICARE) compares standard care with an intervention using a mobile digital health platform enhanced with interactive modules to improve management of the Three Highs. The second trial (DREAM-G) investigates whether taking antihypertensive medications at bedtime versus in the morning better controls morning home blood pressure in patients with elevated morning readings. Participants undergo detailed blood pressure monitoring and medication adjustments based on a stepwise protocol targeting morning hypertension. Both trials include follow-up periods extending up to two years after enrollment. Participants will engage in regular home blood pressure monitoring using the "722 protocol" and attend clinic visits for laboratory and imaging assessments at multiple time points over 24 months. Data collected include blood pressure, lipid levels, glucose control, kidney function, and signs of organ damage. The trials also feature AI-assisted analysis, lifestyle education, and digital communication tools to support therapy adherence and health management. Outcomes focus on blood pressure control, lipid and glucose targets, kidney and cardiovascular health, and safety monitoring throughout the study period.
CONDITIONS
Brief Title
New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with hypertension, defined by office blood pressure readings over 130/80 mmHg or home blood pressure averages exceeding 130/80 mmHg
- Diagnosis of hyperlipidemia with LDL cholesterol above 100 mg/dL, or above 70 mg/dL if diabetes or cardiovascular disease is present
- Diagnosis of diabetes with HbA1c greater than 6.5%, with or without treatment
- Chronic kidney disease with estimated glomerular filtration rate less than 60 mL/min/1.73 m² and urine albumin-to-creatinine ratio above 30 mg/g
- Presence of atherosclerotic cardiovascular disease, including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology
- For the DREAM-G trial: morning home blood pressure over 130/80 mmHg, with weekly averages or more than half of measurements exceeding this threshold
- Willingness to participate in home blood pressure monitoring and follow study procedures
You will not qualify if you...
- Symptomatic heart failure classified as New York Heart Association class II-IV
- End-stage renal disease requiring long-term dialysis
- Pregnancy or planning pregnancy
- Life expectancy less than 1 year
- End-stage renal disease requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care
- Severe liver cirrhosis
- Active treatment for malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Duration - 3 years of enrollment with 2 years of follow-up
Participants undergo treatment involving either selective nocturnal or universal morning antihypertensive dosing, or use of a mobile digital health platform with or without interactive modules to manage hypertension, hyperlipidemia, and hyperglycemia.
Monthly home blood pressure monitoring; laboratory and imaging assessments at baseline and months 2, 4, 6, 12, 14, 16, 20, and 24
Duration - 2 years after enrollment completion
Participants continue to be monitored for blood pressure control, lipid levels, glycemic control, and target organ damage through ongoing assessments and digital health platform interactions.
Home blood pressure recorded every 2 months during follow-up
Trial Site Locations
Total: 1 location
1
United safety medical group(USMG)
New Taipei City, Taiwan
Actively Recruiting
Research Team
H
Hung-Shun Yen Principal Investigator
T
Tzung-Dau Wang Co-Principal Investigator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here